| 1. |
- Hagberg, Johan, et al.
(author)
-
Nordic retail research : An introduction
- 2012
-
In: Nordic Retail Research: Emerging Diversity. - : BAS Publishers. - 9789172463110 ; , s. 19-32
-
Book chapter (other academic/artistic)abstract
- A presentation of retailing in the Nordic countries together with an introduction to the anthology and the co-authors.
|
|
| 2. |
- Alassaad, Anna, 1977-, et al.
(author)
-
A tool for prediction of risk of rehospitalisation and mortality in the hospitalised elderly : secondary analysis of clinical trial data
- 2015
-
In: BMJ Open. - : BMJ. - 2044-6055. ; 5:2
-
Journal article (peer-reviewed)abstract
- Objectives: To construct and internally validate a risk score, the '80+ score', for revisits to hospital and mortality for older patients, incorporating aspects of pharmacotherapy. Our secondary aim was to compare the discriminatory ability of the score with that of three validated tools for measuring inappropriate prescribing: Screening Tool of Older Person's Prescriptions (STOPP), Screening Tool to Alert doctors to Right Treatment (START) and Medication Appropriateness Index (MAI). Setting: Two acute internal medicine wards at Uppsala University hospital. Patient data were used from a randomised controlled trial investigating the effects of a comprehensive clinical pharmacist intervention. Participants: Data from 368 patients, aged 80 years and older, admitted to one of the study wards. Primary outcome measure: Time to rehospitalisation or death during the year after discharge from hospital. Candidate variables were selected among a large number of clinical and drug-specific variables. After a selection process, a score for risk estimation was constructed. The 80+ score was internally validated, and the discriminatory ability of the score and of STOPP, START and MAI was assessed using C-statistics. Results: Seven variables were selected. Impaired renal function, pulmonary disease, malignant disease, living in a nursing home, being prescribed an opioid or being prescribed a drug for peptic ulcer or gastroesophageal reflux disease were associated with an increased risk, while being prescribed an antidepressant drug (tricyclic antidepressants not included) was linked to a lower risk of the outcome. These variables made up the components of the 80+ score. The C-statistics were 0.71 (80+), 0.57 (STOPP), 0.54 (START) and 0.63 (MAI). Conclusions: We developed and internally validated a score for prediction of risk of rehospitalisation and mortality in hospitalised older people. The score discriminated risk better than available tools for inappropriate prescribing. Pending external validation, this score can aid in clinical identification of high-risk patients and targeting of interventions.
|
|
| 3. |
- Alassaad, Anna, 1977-, et al.
(author)
-
A tool for prediction of risk of rehospitalization and mortality in hospitalized elderly
-
Journal article (peer-reviewed)abstract
- Importance: Older patients with multiple co-morbidities and multi-drug use are at high risk of revisits to hospital and mortality, which poses an increasing health economic burden.Objective: To construct and internally validate a risk score, the “80+ score”, for revisits to hospital and mortality for older patients, incorporating aspects of pharmacotherapy. Our secondary aim was to compare the discriminatory ability of the score with that of three validated tools for measuring inappropriate prescribing: Screening Tool of Older Person’s Prescriptions (STOPP), Screening Tool to Alert doctors to Right Treatment (START) and Medication Appropriateness Index (MAI).Design: Secondary use of data from a randomized controlled trial investigating effects of a comprehensive pharmacist intervention, conducted in 2005-2006.Setting: Two acute internal medicine wards at Uppsala University hospital.Participants: Data from 368 patients, 80 years and older, admitted to one of the study wards.Main outcomes and measures: Time to rehospitalization or death during the year after discharge from hospital. Candidate variables were selected among a large number of clinical and drug-specific variables. After a selection process, a score for risk-estimation was constructed. The score was internally validated, and the discriminatory ability of the new score and of STOPP, START and MAI was assessed using C-statistics. Results: Seven variables were selected for the 80+ score. Impaired renal function, pulmonary disease (chronic obstructive pulmonary disease [COPD or asthma]), malignant disease (past or present), living in nursing home, being prescribed an opioid or being prescribed a drug for peptic ulcer or gastroesophageal reflux disease was associated with an increased risk, while being prescribed an antidepressant drug (tricyclic antidepressants not included) was linked to a lower risk of the outcome. These variables made up the components of the 80+ score. The C-statistics were 0.71 (80+ score), 0.57 (STOPP), 0.54 (START) and 0.63 (MAI). Conclusion and Relevance: We developed and internally validated a score for prediction of risk of rehospitalization and mortality in hospitalized older people. The score discriminated risk considerably better than available tools for inappropriate prescribing. Pending external validation, this score can aid in clinical identification of high-risk patients and targeting of interventions.
|
|
| 4. |
- Alassaad, Anna, 1977-, et al.
(author)
-
The effects of pharmacist intervention on emergency department visits in patients 80 years and older : subgroup analyses by number of prescribed drugs and appropriate prescribing
- 2014
-
In: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 9:11, s. e111797-
-
Journal article (peer-reviewed)abstract
- Background: Clinical pharmacist interventions have been shown to have positive effect on occurrence of drug-related issues as well as on clinical outcomes. However, evidence about which patients benefiting most from the interventions is limited. We aimed to explore whether pharmacist intervention is equally effective in preventing emergency department (ED) visits in patients with few or many prescribed drugs and in those with different levels of inappropriate prescribing. Methods: Patient and outcome data from a randomized controlled trial exploring the clinical effects of a ward-based pharmacist intervention in patients, 80 years and older, were used. The patients were divided into subgroups according to the number of prescribed drugs (< 5 or >= 5 drugs) and the level of inappropriate prescribing [using the Screening Tool Of Older People's potentially inappropriate Prescriptions (STOPP) and the Screening Tool to Alert doctors to Right Treatment (START) with a score of >= 2 (STOPP) and >= 1 (START) as cutoff points]. The effect of the intervention on the number of times the different subgroups visited the ED was analyzed. Results: The pharmacist intervention was more effective with respect to the number of subsequent ED visits in patients taking < 5 drugs on admission than in those taking >= 5 drugs. The rate ratio (RR) for a subsequent ED visit was 0.22 [95% confidence interval (CI) 0.09-0.52] for,5 drugs and 0.70 (95% CI 0.47-1.04) for >= 5 drugs (p = 0.02 for the interaction). The effect of intervention did not differ between patients with high or low STOPP or START scores. Conclusion: In this exploratory study, the pharmacist intervention appeared to be more effective in preventing visits to the ED for patients who were taking fewer drugs before the intervention. Our analysis of STOPP and START scores indicated that the level of inappropriate prescribing on admission had no effect on the outcomes of intervention with respect to ED visits.
|
|
| 5. |
- Andreasson, Ulrika, et al.
(author)
-
Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells
- 2009
-
In: American Journal of Hematology. - : Wiley. - 0361-8609 .- 1096-8652. ; 84:12, s. 803-808
-
Journal article (peer-reviewed)abstract
- Follicular lymphoma (FL) frequently transforms into the more aggressive diffuse large B cell lymphoma (DLBCL-tr), but no protein biomarkers have been identified for predictive or early diagnosis. Gene expression analyses have identified genes changing on transformation but have failed to be reproducible in different studies, reflecting the heterogeneity within the tumor tissue and between tumor samples. Gene expression analyses on Affymetrix Human Genome U133 Plus 2.0 arrays were performed, using flow cytometry sorted tumor cells derived from FL and transformed DLBCL. To identify molecular targets associated with the transformation, subsequent immunohistochemistry (IHC) analyses of the corresponding proteins were performed. Using highly purified cells, this study identified 163 genes, which were significantly deregulated during the transformation in a majority of cases. Among the upregulated transcripts, 13 genes were selected for validation using IHC, based on the availability of commercial antibodies, and galectin-3 and NEK2 proteins specifically identify DLBCL-tr, when compared with FL. We demonstrate that by purifying tumor cells through cell sorting, thereby reducing the heterogeneity due to infiltrating cells, it was possible to identify distinct differences between tumor entities rather than variations due to cellular composition. Galectin-3 and NEK2 both identified a subgroup of DLBCL-tr, and the function of these protein markers also suggests a biological role in the transformation process.
|
|
| 6. |
- Andreasson, Ulrika, et al.
(author)
-
Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.
- 2010
-
In: American Journal of Hematology. - : Wiley. - 0361-8609 .- 1096-8652. ; 85:6, s. 418-425
-
Journal article (peer-reviewed)abstract
- Transcription factors (TFs) are critical for B-cell differentiation, affecting gene expression both by repression and transcriptional activation. Still, this information is not used for classification of B-cell lymphomas (BCLs). Traditionally, BCLs are diagnosed based on a phenotypic resemblance to normal B-cells; assessed by immunohistochemistry or flow cytometry, by using a handful of phenotypic markers. In the last decade, diagnostic and prognostic evaluation has been facilitated by global gene expression profiling (GEP), providing a new powerful means for the classification, prediction of survival, and response to treatment of lymphomas. However, most GEP studies have typically been performed on whole tissue samples, containing varying degrees of tumor cell content, which results in uncertainties in data analysis. In this study, global GEP analyses were performed on highly purified, flow-cytometry sorted tumor-cells from eight subgroups of BCLs. This enabled identification of TFs that can be uniquely associated to the tumor cells of chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), hairy cell leukemia (HCL), and mantle cell lymphoma (MCL). The identified transcription factors influence both the global and specific gene expression of the BCLs and have possible implications for diagnosis and treatment.
|
|
| 7. |
- Beckeman, Märit, et al.
(author)
-
The importance of packaging innovations in the Swedish food sector
- 2012
-
In: Nordic Retail Research: Emerging diversity. ; , s. 193-211
-
Book chapter (peer-reviewed)abstract
- Abstract in Undetermined Packaging is of particular importance to retailers, since it can be considered an integral part of the product and the first point of contact with the brand (Rundh 2005). Over 73% of interviewed consumers rely on packaging to aid their purchasing decisions (Wells et al. 2007), and retailers are the ‘gatekeepers’ to the consumers (Dobson et al. 2003) via the retail stores, where the packaging of a product is what meets the eyes of consumers. Young (2008:26) simply states, “The package is the product”, and packaging “combines the ‘4 Ps’ of marketing: the package contains the product, packages convey messages about product attributes to consumers as part of public relations, and often its price, while also carrying promotions”, making it an integral part of the product (Hawkes 2010:297). Hence, innovations in packaging and packaging systems in the food sector are intimately connected with the contained products; success or failure can be due to either or both aspects. And the success rate of food products is low: 80 to 90% of all launched products fail within the first year, in the USA (Rudolph 1995), with similar figures in other countries. This might be due to shortcomings in the methodology to develop (Stewart-Knox & Mitchell 2003) or that the right business model to “capture value from innovations” has not been designed (Teece 2010:183). And “value exists only if the consumer perceives it as such” (Burt 1989:29). Today, many retailers control the supply chain from producers to consumers (Fernie & Sparks 2009), have expanded their range of differentiated private labels (Burt & Sparks 2002) and increasingly compete with manufacturers’ brands, including in Sweden (Beckeman & Olsson 2011). This has resulted in increased demands for more flexible production to meet a greater variety of packaging sizes, products, recipes and delivery on demand, without increasing The importance of packaging innovations in the Swedish food sector 11 194 Chapter 11 the costs, and consequently smaller order sizes and varying designs (Van Donk 2001; Van Donk et al. 2008). The real breakthrough for packaged food in Sweden came with the introduction of frozen food in 1945 and self-service stores in 1947, both of which demanded packaging (Beckeman 2006). These changes initiated efficient supply chains, which together with a value perspective have become a necessity for the different requirements of various food products (Fisher 1997; Gustafsson et al. 2006). Food and beverages range from dry products to liquids, requiring distribution/storage temperatures from ambient, via refrigerated to frozen. Hence, product demands on packaging vary. The broader background to this chapter can be found in a doctoral thesis (Beckeman 2011) based on interviews with retailers, food manufacturers and packaging suppliers active in Sweden. To our knowledge, no similar investigation of the Swedish food sector of today has been carried out. The purpose was to investigate how the three groups of actors view innovations in their own area, their roles and the roles of other actors in the chain; i.e. if there is a gap of opinions about innovations among them. This chapter summarises the results from interviewing packaging suppliers based on the following research questions: • How do innovative Swedish packaging suppliers define innovations, and how do they regard their own role in food innovations? • What is the nature of the collaboration among packaging suppliers and other actors in the supply chain regarding food innovations? ‘Consumer’ is defined as the end consumer of a food product, whereas a ‘customer’ can be a food manufacturer, a retailer or the next link in the packaging supply chain, as packaging suppliers cannot be defined as one homogenous group. They can be material producers, packaging converters, packaging machinery suppliers and other relevant suppliers (Paine 2002), and can work as partners, sub-suppliers and/or competitors with each other, depending on the situation and the demands. In this mixture of packaging suppliers, some are considered more innovative and successful than others, as previously suggested by interviewed retailers (Beckeman & Olsson 2011) and food manufacturers (Beckeman et al., in press) and are the focus of this study. This chapter is organised as follows: it starts by summarising literature on packaging and packaging functions and related to food innovations, continues with methodology, including framework for analysis, which is followed by results and analysis, and ends with conclusions.
|
|
| 8. |
- Bogdanska, Jasna, et al.
(author)
-
Tissue distribution of (35)S-labelled perfluorooctane sulfonate in adult mice after oral exposure to a low environmentally relevant dose or a high experimental dose
- 2011
-
In: Toxicology. - : Elsevier BV. - 0300-483X .- 1879-3185. ; 284:1-3, s. 54-62
-
Journal article (peer-reviewed)abstract
- The widespread environmental pollutant perfluorooctane sulfonate (PFOS), detected in most animal species including the general human population, exerts several effects on experimental animals, e.g., hepatotoxicity, immunotoxicity and developmental toxicity. However, detailed information on the tissue distribution of PFOS in mammals is scarce and, in particular, the lack of available information regarding environmentally relevant exposure levels limits our understanding of how mammals (including humans) may be affected. Accordingly, we characterized the tissue distribution of this compound in mice, an important experimental animal for studying PFOS toxicity. Following dietary exposure of adult male C57/BL6 mice for 1-5 days to an environmentally relevant (0.031 mg/kg/day) or a 750-fold higher experimentally relevant dose (23 mg/kg/day) of (35)S-PFOS, most of the radioactivity administered was recovered in liver, bone (bone marrow), blood, skin and muscle, with the highest levels detected in liver, lung, blood, kidney and bone (bone marrow). Following high daily dose exposure, PFOS exhibited a different distribution profile than with low daily dose exposure, which indicated a shift in distribution from the blood to the tissues with increasing dose. Both scintillation counting (with correction for the blood present in the tissues) and whole-body autoradiography revealed the presence of PFOS in all 19 tissues examined, with identification of thymus as a novel site for localization for PFOS and bone (bone marrow), skin and muscle as significant body compartments for PFOS. These findings demonstrate that PFOS leaves the bloodstream and enters most tissues in a dose-dependent manner.
|
|
| 9. |
|
|
| 10. |
- Bogdanska, Jasna, et al.
(author)
-
Tissue distribution of S-35-labelled perfluorobutanesulfonic acid in adult mice following dietary exposure for 1-5 days
- 2014
-
In: Chemosphere. - : Elsevier BV. - 0045-6535 .- 1879-1298. ; 98, s. 28-36
-
Journal article (peer-reviewed)abstract
- Perfluorobutanesulfonyl fluoride (PBSF) has been introduced as a replacement for its eight-carbon homolog perfluorooctanesulfonyl fluoride (POSF) in the manufacturing of fluorochemicals. Fluorochemicals derived from PBSF may give rise to perfluorobutanesulfonic acid (PFBS) as a terminal degradation product. Although basic mammalian toxicokinetic data exist for PFBS, information on its tissue distribution has only been reported in one study focused on rat liver. Therefore, here we characterized the tissue distribution of PFBS in mice in the same manner as we earlier examined its eight-carbon homolog perfluorooctanesulfonate (PFOS) to allow direct comparisons. Following dietary exposure of adult male C57/BL6 mice for 1,3 or 5 d to 16 mg S-35-PFBS kg(-1) d(-1), both scintillation counting and whole-body autoradiography (WBA) revealed the presence of PFBS in all of the 20 different tissues examined, demonstrating its ability to leave the bloodstream and enter tissues. After 5 d of treatment the highest levels were detected in liver, gastrointestinal tract, blood, kidney, cartilage, whole bone, lungs and thyroid gland. WBA revealed relatively high levels of PFBS in male genital organs as well, with the exception of the testis. The tissue levels increased from 1 to 3 d of exposure but appeared thereafter to level-off in most cases. The estimated major body compartments were whole bone, liver, blood, skin and muscle. This exposure to PFBS resulted in 5-40-fold lower tissue levels than did similar exposure to PFOS, as well as in a different pattern of tissue distribution, including lower levels in liver and lungs relative to blood.
|
|
